Ocular Pharmaceuticals
New and emerging ocular drugs are improving treatment outcomes and patient convenience. "Ocular Drug Preview: Spotlight on Emerging Pharmaceuticals," in the December 2004 issue of Review of Optometry, offers a look at many ocular pharmaceuticals currently in use or in clinical trials. Major eye conditions and medications covered:
Glaucoma --Existing glaucoma medications are being tested in new combinations that may be easier for patients to manage and may result in better control of intraocular pressure. Oral calcium channel blockers, which reduce vasospasm - an abnormal, sudden and involuntary contraction of blood vessels - are being used to increase blood flow and volume to the optic nerve. A topical calcium channel blocker is in development. Clinical studies are also underway to find medications that might protect the optic nerve and retinal ganglion cells.
Infections -- Fluoroquinolones are currently being used to treat many ocular infections. Additional investigational antibiotics may soon become available to treat eye inflammations and infections.
Inflammation and Pain -- Topical non-steroidal anti-inflammatory drug (NSAID) solutions are used to control inflammation following cataract surgery, reduce complications from refractive procedures and reduce pain associated with corneal procedures. New NSAIDs are being developed for less frequent dosing and reduced burning and stinging when applied.
Dry Eye -- Medications are being researched to increase mucin production, supplement the tear film, and enhance lacrimal gland secretory function.
For additional information about promising new drugs on the horizon, visit the Review of Optometry Web site.
|
NEW Online Courses!
|
